My comments are minor in nature and in the main are given in order to suggest improvements to the flow and structure of the report. I have enjoyed reading it and I am sure it will be a useful addition to the body of patient involvement literature.
Background
Although the last sentence of the background gives information on what the editorial policy of the BMJ enabled, a clear statement of the aim(s) of this paper is not given. An extra sentence to help signpost the reader would be helpful.
Methods
In the inclusion criteria section it is made clear that you have not excluded any 'study designs'. However the BMJ regularly publishes methods papers which may therefore not have a specific study design but still be considered a 'research paper'. How did you determine whether or not to include/exclude these papers? I appreciate that the BMJ also publishes other types of paper/article e.g. commentaries, editorials etc. so some further information on how the categorisation of 'research paper' was achieved might be helpful. I think that some of my ambiguity here is because sometimes the words 'studies' and 'papers' are used interchangeably.
Results
In the frequency section in the first paragraph of each of the subsections labelled 'pre-implementation sample' and 'postimplementation sample' you have highlighted the number of papers that had a corresponding author based in the UK. Although BMJ is published in the UK its authorship is international and because the study is about frequency and type of PI reported, I am not sure why this statistic has been included.
It is interesting to note that in your description of the Hull study you mention 'US patients' but in the Richards study you do not mention the demographic of the study population. This inconsistency is also present in the post-implementation descriptions with 3 of the 4 descriptions giving location. Is the location/demographic an important part of your study description given that this is not analysed separately to determine patterns of PI involvement? Perhaps this could be adjusted to show some consistency in reporting.
I like the inclusion of the four examples of PI activity as this gives readers some clear evidence of how PI has been included in those studies. I wonder whether this section could be made more useful by giving some indication of how you chose these examples: e.g. was your choice based on the level of description of PI in the original papers, was it based on your analysis of comprehensive PI etc.? Did you think about including an example or two where PI was much less comprehensively reported? This might give more balance to this section.
In the description of the STOP GAP trial your final sentence is "It was of interest that members of the UK Dermatology Clinical Trials Network also identified this research as being a priority area" -I am not sure why this is included as it does not reflect PI involvement.
PI in dissemination I am not keen on the first sentence where the pre and post implementation samples appear to be compared by using the phrase 'greater emphasis': in the previous section when directing readers to table 3 you state it is not appropriate to compare the type of reporting between the two samples due to the very small preimplementation sample -should this not apply to all facets of the reporting? I think this beginning sentence could benefit from some rewording to removed the 'greater emphasis' phrase.
Research funding I am not sure why this section is included as unless the funding stream relates directly to whether PI was included (e.g. papers reported that funds were set aside to enable PI), it does not relate to the aim of your paper. Table three has five, clearly defined topics related to PI involvement and I wonder why these were not used to structure the results section? I think you have captured many of the issues elucidated by your data, however I think some important points might have been lost -e.g. in the study design section of table 3 44% of papers report patient involvement in the development of outcome measures and 44% report assessment of the burden of the intervention; in the study conduct section 50% report patients being involved with recruitment and implementation. Given that organisations such as INVOLVE etc commend the involvement of patients at these early stages I think you could consider signposting your readers more overtly to these statistics and then follow up in the discussion.
General comment about results section

Discussion
Could first sentence be changed to 'based on this analysis…' 4th line: The sentence "however researchers within our cohorts…" is a little ambiguous. Do you mean "researchers who conducted the studies we sampled…"? I like that you have picked up the types of involvement of patients in the opening paragraph as this sets the scene for the rest of the discussion really well. I wonder whether this could be linked back more overtly to the results section by having these points and the associated stats more clearly outlined in the results section?
In paragraph 2, line 4/5 you have given the statistic of 11% for reporting of PI. This relates to the post-implementation reporting only, so your wording here needs to make that clear.
Much of your 4th paragraph in the discussion reads as an evaluation of the GRIPP 2 tool. Whilst I do not think this is inappropriate, I think that the paragraph could be changed such that the issue of reporting of PI is the main focus, giving GRIPP2 as a good example of how this might occur in practice.
Is the point about improved reporting of PI reducing research waste etc more suited as a background point rather than a discussion point? How does this point relate to the findings of your study?
Similarly the last two sentences of that paragraph beginning "Journals can encourage or mandate authors to report PI…" seem more suited to the conclusion.
The final paragraph of the discussion seems to be more suited to the background as it helps set out/give rationale for the purpose of this paper.
Conclusion section final sentence "can't" should be "cannot"
REVIEWER
Christopher McKevitt King's College London UK REVIEW RETURNED 06-Dec-2017
GENERAL COMMENTS
This paper explores the impact of requiring authors who submit research papers to the British Medical Journal to report, as part of the submission process how patients were involved in the research. The paper takes 'before and after' samples and finds that in the year before the introduction of the policy 1% of published research papers reported PPI activity. In the year following the introduction of the policy, 11% reported PPI activity. The study design means that it is not possible to say much about this change, or why reporting PPI activity remained 'low'. The authors conclude that there must be 'substantial perceived or actual barriers to involving patients in research', that this requires further investigation, but the role of editors and journals in enabling widespread implementation of involvement in research is limited. This paper meaningfully adds to the literature, which includes very little evaluative information about public involvement in research. The study leverages a unique opportunity-the policy change at BMJ about reporting PI-to answer some key questions about the prevalence of PI activity and reporting. Overall, the paper is well written and uses methods appropriate to answer the research questions.
There are opportunities to increase the reproducibility of the methods and the clarity of the key messages to increase the impact of the paper.
The paper can more clearly articulate underlying assumptions, expectations and/or learnings about the extent to which the limited information on PI in the literature within the context of clinical research is attributable to a lack of reporting and/or a lack of PI activity-both in the description of the purpose of the work in the introduction, and the explanation of the findings in the discussion section. For example, the paper could overtly recognize on pg 11, line 10 that if not largely attributable to a lack of reporting, the low proportion of studies reporting PI may be due to lack of PI. -
The authors should address why research teams that used PI for their projects would publish papers that do not report PI in the paper (what key contextual, resource, and/or cultural factors are at play) and the implication for this study and its findings. -Throughout the paper, the authors refer to 'acknowledgement' of patients' contributions-it's not immediately clear as written how this concept is operationally defined, how this differs from discussion with the text of the paper about contributions to the project (as recommended in the GRIPP2 reporting check list).
(After a few reads, it appears the authors are looking separately at general discussions about PI vs. acknowledgement of the specific people who contributed, although more clarity would help.) -
The background section would benefit from more information about how/why the BMJ felt that reporting PI would foster increased collaboration between researchers and the public and on any moral imperatives or principled stances related to showing that researchers value the public's contributions. -Regarding the study Methods: o Did the policy implemented on June 1, 2014 apply to papers submitted after that date or papers published after that date? Does the sample of papers published during these time periods thus relate appropriately to the implementation of the policy? o How was it determined that authors were members of the public? Same question for people mentioned in the acknowledgements? o If there is an assumption that more PI occurs than is reported in the literature, the study would be strengthened by reviewing the acknowledgements of all the papers in the pre-implementation sample to see if there is additional info about PI not described in the body of the papers. -It's not clear why this paper uses the term public involvement (PI) rather than patient and public involvement (PPI) (in fact in the abstract, they refer to 'patients'). It would be easier for readers to see PPI or understand why the need for a new term. Secondarily, the abbreviation PI is easily confused with Principal Investigator, also abbreviated PI. -2 nd paragraph of Discussion-The authors provide explanations for why the proportion of papers reporting PI might be lower than UK reports of the frequency of PI. However, PI is not yet the norm in the US and other countries and the samples included relative small proportions of papers funded from the UK.
Other readily addressable points--In the abstract (objective)-the limited knowledge about the frequency of PI is, at least in part, attributable to the lack of consistent way of reporting PI. -First paragraph of the background section-the authors distinguish PI from lesser forms of involvement, including public 'engagement' in research. The authors should use a different word, given that patient and public 'engagement' is the term used to describe PI in the US.
-
The paper includes results on several relevant aspects related PI -including PI for dissemination, research funding source, and acknowledgement for PI activity. The paper would be strengthened if the authors more fully set up in the background the questions the paper will answer. -The Macaulay article, describing a planned review, doesn't support well the assertion that research involving patients as partners improves the quality of research.
The term 'rate' in an epidemiologic context refers to the frequency of an event relative to time. For the measure in this paper, other terms like frequency, proportion or prevalence would be more appropriate.
The information shared in this paper can serve as a baseline for funders, journals, academic institutions, and others interested in facilitating PI, against which future assessments can be compared. -Page 8-description of the REACT trial-more info is needed about how input was received from the public. -Page 8 -the last sentence "one study author named…."-this is a critical sentence explaining the impact of PI on that project. The paper would be strengthened if this sentence was written more clearly and in a more straightforward way. -Concannon et al (2014) also includes guidance about reporting on patient engagement in research.
The authors point to funding agencies requiring the 'declaration' of PI-would it be more accurate to say that increasingly funders are requiring PI? The reference to support this point (#42) is not on the reference list.
VERSION 1 -AUTHOR RESPONSE
Editors comments: 1. Please revise the 'Strengths and limitations' section of your manuscript. This section should relate specifically to the methods, and should not include a general summary of, or the results of, the study.
This section only refers to the methods section of our manuscript and does not include any results (see page 3).
2) Please ensure that your abstract is formatted according to our Instructions for Authors: http://bmjopen.bmj.com/pages/authors/#research Revised -see page 2.
3) Please modify the 'Consent for publication' statement provided. Consent for publication is only required if a manuscript contains details, images, or videos relating to individual participants. As your manuscript does not contain individual participant data consent for publication is not required.
We have removed this.
Reviewer(s)' Comments to Author: Reviewer: 1 1) Although the last sentence of the background gives information on what the editorial policy of the BMJ enabled, a clear statement of the aim(s) of this paper is not given. An extra sentence to help signpost the reader would be helpful.
We have made the objectives of the study clearer -see final paragraph in background section.
2) In the inclusion criteria section it is made clear that you have not excluded any 'study designs'. However the BMJ regularly publishes methods papers which may therefore not have a specific study design but still be considered a 'research paper'. How did you determine whether or not to include/exclude these papers? I appreciate that the BMJ also publishes other types of paper/article e.g. commentaries, editorials etc. so some further information on how the categorisation of 'research paper' was achieved might be helpful. I think that some of my ambiguity here is because sometimes the words 'studies' and 'papers' are used interchangeably.
The methodological papers referred to are published under a different section from research papers (Research Methods and Reporting). We only included papers describing original research published under the section of Research. We have tried to make this clearer (page 6). We have also tried to be more consistent with our use of "studies" and "papers" throughout.
3) In the frequency section in the first paragraph of each of the subsections labelled 'preimplementation sample' and 'post-implementation sample' you have highlighted the number of papers that had a corresponding author based in the UK. Although BMJ is published in the UK its authorship is international and because the study is about frequency and type of PI reported, I am not sure why this statistic has been included.
We have now removed this contextual information.
4) It is interesting to note that in your description of the Hull study you mention 'US patients' but in the Richards study you do not mention the demographic of the study population. This inconsistency is also present in the post-implementation descriptions with 3 of the 4 descriptions giving location. Is the location/demographic an important part of your study description given that this is not analysed separately to determine patterns of PI involvement? Perhaps this could be adjusted to show some consistency in reporting.
We have revised this by deleting country information throughout. 5) I like the inclusion of the four examples of PI activity as this gives readers some clear evidence of how PI has been included in those studies. I wonder whether this section could be made more useful by giving some indication of how you chose these examples: e.g. was your choice based on the level of description of PI in the original papers, was it based on your analysis of comprehensive PI etc.? Did you think about including an example or two where PI was much less comprehensively reported? This might give more balance to this section.
We have added more information about how we chose these four examples on p9. We wanted to draw attention to examples of good practice rather than less good. "These examples were chosen as they describe a range of approaches to involving patients at different stages in the research process. For more details of how other papers in the postimplementation period reported PPI see Table 2 ." 6) In the description of the STOP GAP trial your final sentence is "It was of interest that members of the UK Dermatology Clinical Trials Network also identified this research as being a priority area" -I am not sure why this is included as it does not reflect PI involvement.
We thought it added some context but have now removed this. 7) PI in dissemination -I am not keen on the first sentence where the pre and post implementation samples appear to be compared by using the phrase 'greater emphasis': in the previous section when directing readers to table 3 you state it is not appropriate to compare the type of reporting between the two samples due to the very small pre-implementation sample -should this not apply to all facets of the reporting? I think this beginning sentence could benefit from some rewording to remove the 'greater emphasis' phrase.
We have revised this -see page 9 paragraph 2. 8) Research funding -I am not sure why this section is included as unless the funding stream relates directly to whether PI was included (e.g. papers reported that funds were set aside to enable PI), it does not relate to the aim of your paper.
We have removed all mention of funding. 9) General comment about results section. Table three has five, clearly defined topics related to PI involvement and I wonder why these were not used to structure the results section? I think you have captured many of the issues elucidated by your data, however I think some important points might have been lost -e.g. in the study design section of table 3 44% of papers report patient involvement in the development of outcome measures and 44% report assessment of the burden of the intervention; in the study conduct section 50% report patients being involved with recruitment and implementation. Given that organisations such as INVOLVE etc commend the involvement of patients at these early stages I think you could consider signposting your readers more overtly to these statistics and then follow up in the discussion.
We have restructured the Results section. We have added more detail from Table 3 to the main text in the Results section as suggested and commented on some of this in the Discussion. 10) Discussion -Could first sentence be changed to 'based on this analysis…' Revised -see page 12.
11) 4th line: The sentence "however researchers within our cohorts…" is a little ambiguous. Do you mean "researchers who conducted the studies we sampled…"?
Revised -see page 12.
12) I like that you have picked up the types of involvement of patients in the opening paragraph as this sets the scene for the rest of the discussion really well. I wonder whether this could be linked back more overtly to the results section by having these points and the associated stats more clearly outlined in the results section?
We have restructured the Results section in response to this comment. 13) In paragraph 2, line 4/5 you have given the statistic of 11% for reporting of PI. This relates to the post-implementation reporting only, so your wording here needs to make that clear.
We have revised this statement in response to comments from Reviewers 1 and 3 -see page 12.
14) Much of your 4th paragraph in the discussion reads as an evaluation of the GRIPP 2 tool. Whilst I do not think this is inappropriate, I think that the paragraph could be changed such that the issue of reporting of PI is the main focus, giving GRIPP2 as a good example of how this might occur in practice.
We have revised this paragraph as suggested. 15) Is the point about improved reporting of PI reducing research waste etc more suited as a background point rather than a discussion point? How does this point relate to the findings of your study?
We have kept this in the Discussion section because what is not reported is difficult to replicate and leads to a shortage of shared experience of what works in practice. This wastes resources, expertise and time that could be put to better use than people reinventing the wheel for PPI and reporting on this rather than progressing to the refinement of best practice. We have tied this to our results. 16) Similarly the last two sentences of that paragraph beginning "Journals can encourage or mandate authors to report PI…" seem more suited to the conclusion.
We have revised this and moved it to the Conclusion.
17) The final paragraph of the discussion seems to be more suited to the background as it helps set out/give rationale for the purpose of this paper.
We feel this is a Discussion point and have tried to make it clearer.
18) Conclusion section final sentence "can't" should be "cannot"
Revised -see page 15.
Reviewer: 2 1) For me, the authors (nearly all employed by the BMJ) fail to ask an obvious question about editorial practice in the BMJ. If reporting PPI is 'mandatory' in the submission process, why did 89% of papers get published in the study period despite failing a mandatory requirement. Perhaps the BMJ needs to look at its own red lines as a starting point. Or perhaps the policy is not actually mandatory. I was confused about this. It is described as mandatory in the manuscript yet the BMJ statement reported in Box 1 seems to be couched in other terms -'encouraging patient involvement', 'request that authors provide a statement'.
Sorry for the confusion. The statement is mandatory, the inclusion of PPI as a condition of publicati on is not. We have now made it clearer throughout that this is a routine declaration request to authors at the time of submission for all research papers. For all papers that are accepted for publication we check again that this information is included in the papers and if it is absent we request authors again to include it. 12 (8%) of the 152 papers published in our post-implementation sample did not include a Patient Involvement section in the article. There are several possible reasons for this including human error as we began to roll out a new journal initiative with multiple editors and the fact that some papers will have been submitted before we introduced the policy so didn't include the PI statement on submission and then wasn't checked at publication stage. We have now removed Box 1 and put the information in the main text to avoid confusion by other readers.
"why did 89% of papers get published in the study period despite failing a mandatory requirement"? Reviewer 2 is confused, 89% did not fail a mandatory requirement. 11% of papers reported some actual involvement of patients and the remaining 89% did not involve patients in their studies and reported that in their statement or there was an absence of this information in the paper (for the papers that did not include a PPI statement). We do not refuse to publish articles that do not involve patients but we do ask authors to report how they involved patients and if they did not to make this clear. This was all documented in Box 1 but we have now made it clearer in the main text.
2) It is unclear therefore what the role of the BMJ is in this case and how much store we should set by the apparent failure to implement policy.
As described above, there has not been a failure to implement policy.
3) The terminology needs clarification. The BMJ statement speaks of patient involvement; the authors use the term public involvement and INVOLVE talk of patient and Public Involvement. They also use some terms which are commonplace in PPI circles but whic h need defining or justifying, for example, 'active partners', 'active participation' or 'good PI'.
There is a lack of consistency in the use of terminology in this area. We initially decided on the term Patient Involvement in this manuscript as that is the section heading The BMJ requests authors to include in their research papers. However, to avoid confusion for the wider readership of this article we have reverted to PPI throughout. We have clarified the other terms as well and avoid the use of "good PPI".
4) The authors use the well-known definition of patient and public involvement from INVOLVE. I find this rather a narrow and UK-centric definition of lay-scientist interaction which historically has taken different forms, and which currently takes place in diverse ways across the globe.
Reviewer 2 suggests we expand the definition to include more forms of PPI. We did user test this option with patient volunteers and others. They suggested that as it is a paper about analysis of PPI in a general medical journal that we keep it simple and straightforward and in line with what we already used to explain the concept to prospective authors. BMJ authors are certainly encouraged to elaborate on definitions within their own papers. The definition we used is basic and fits all types of participatory research and that is why we used it.
5) The abstract needs to be revised to include a clear statement of the aim of the paper. What is currently provided under the heading Objective is background. Nor tis the research question very clear in the body of the manuscript. Is it 1) has the policy made a difference on reporting PPI; what kinds of PPI do those papers accepted by the BMJ conduct and or report. Clarifying the question(s) would make it easier to see why the different types of results are presented.
We have revised the abstract and the last paragraph of the introduction to make this clearer.
6) The boundary between involvement and qualitative research is sometimes blurred and can be porous depending on the objective. However, I would like to see greater justification of why the examples on page 7 of patient focus groups to develop a questionnaire, and in-depth qualitative interviews represent PPI, rather than standard qualitative research.
We agree that this boundary is often blurred and that our presentation of the study by Hull et al was not helpful so we have excluded it. We also mention this issue in the paper as it is a very helpful point.
7) It is unclear how the how the examples of involvement from the published reports of PPI were chosen and what they are intended to represent.
We have made this clearer -see page 9. 8) There are also some issues in relation to reporting for PPI in the PROSPER study (page 8-9) that require clarification. Could the authors describe what it means to partner 'with patients throughout the research process'; I don't understand what is meant by 'the patient inspired integration of "home time" as a study a strength where the longitudinal functional outcomes were prioritised by stroke survivors'; or by the expression 'as trialists retained the rigors of the scientific work.'
We have revised the description of the PROSPER study -see page 10. 9) PROSPER study…….. Reporting that three patient co-investigators were made co-authors on the manuscript raises the question of how they fulfilled the usual criteria for authorship.
Here is a link to The BMJ's guidance on authorship http://www.bmj.com/about-bmj/resources-authors/article-submission/authorship-contributorship This includes detailed advice including: "The BMJ requires that all those designated as authors should meet all four ICMJE criteria for authorship, and all who meet the four criteria should be identified as authors. We recognise only natural persons as authors. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion #s 2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript."
As with all our published papers, the corresponding author of the manuscript will have been asked to indicate that all the authors met the ICMJE criteria. As such, there is no reason to think that these patients were less eligible than any other authors of papers published in The BMJ. Not all patients involved in research will meet authorship criteria (or be given the opportunity to meet the criteria) but these patients are reported to have met the criteria and as such have appropriately been included as co-authors.
10) The authors suggest that we need a better understanding of why PPI is not being done. Here they could draw on the literature that has already sought to look at this question, for example: Snape D, Kirkham J, Britten N, et al. Exploring perceived barriers, drivers, impacts We have revised the text to include these papers and make our points clearer and moved it to the conclusion -see page 15.
Reviewer: 3
1) The paper can more clearly articulate underlying assumptions, expectations and/or learnings about the extent to which the limited information on PI in the literature within the context of clinical research is attributable to a lack of reporting and/or a lack of PI activity -both in the description of the purpose of the work in the introduction, and the explanation of the findings in the dis cussion section. For example, the paper could overtly recognize on pg 11, line 10 that if not largely attributable to a lack of reporting, the low proportion of studies reporting PI may be due to lack of PI.
Revised -we have made this more explicit in the introduction and discussion sections.
2) The authors should address why research teams that used PI for their projects would publish papers that do not report PI in the paper (what key contextual, resource, and/or cultural factors are at play) and the implication for this study and its findings.
Revised -see page 13. "As editors and peer reviewers do not usually request PPI reporting, authors may not consider including it and some may perceive it to have less value than other aspects of the researc h."
3) Throughout the paper, the authors refer to 'acknowledgement' of patients' contributions -it's not immediately clear as written how this concept is operationally defined, how this differs from discussion with the text of the paper about contributions to the project (as recommended in the GRIPP2 reporting checklist). (After a few reads, it appears the authors are looking separately at general discussions about PI vs. acknowledgement of the specific people who contributed, although more clarity would help.)
We have revised the title of the section about acknowledgements and clarified the purpose of the paragraph to make this clearer -see page 11.
4) The background section would benefit from more information about how/why the BMJ felt that reporting PI would foster increased collaboration between researchers and the public and on any moral imperatives or principled stances related to showing that researchers value the public's contributions.
Revised -see page 4. 5) Did the policy implemented on June 1, 2014 apply to papers submitted after that date or papers published after that date? Does the sample of papers published during these time periods thus relate appropriately to the implementation of the policy?
The policy was applied to papers submitted after June 2014, but for accepted papers, editors went back to the authors and asked them to include the information. We have revised the description of the sampling periods to make it clearer. 6) How was it determined that authors were members of the public? Same question for people mentioned in the acknowledgements?
Patient contributors who become co-authors are clearly indicated as such on the author byline in published BMJ articles.
Submitting authors are instructed to thank patients involved in the contributorship statement and or acknowledgments. We do note in the Results section that there were examples where it was not clear if a named and thanked person in the acknowledgements section was a patient/member of the public or someone else providing some other type of assistance. We plan to give more explicit guidance to authors in the future so that this becomes clearer.
7)
If there is an assumption that more PI occurs than is reported in the literature, the study would be strengthened by reviewing the acknowledgements of all the papers in the preimplementation sample to see if there is additional info about PI not described in the body of the papers. This was done, as mentioned in the text under the subheading of Process on page 6 -"Footnotes and contributorship notes were also checked".
8) It's not clear why this paper uses the term public involvement (PI) rather than patient and public involvement (PPI) (in fact in the abstract, they refer to 'patients'). It would be easier for readers to see PPI or understand why the need for a new term. Secondarily, the abbreviation PI is easily confused with Principal Investigator, also abbreviated PI.
We have changed the term to PPI throughout. 9) 2nd paragraph of Discussion-The authors provide explanations for why the proportion of papers reporting PI might be lower than UK reports of the frequency of PI. However, PI is not yet the norm in the US and other countries and the samples included relative small proportions of papers funded from the UK.
We have revised this statement -see para 2 on page 12. 10) In the abstract (objective)-the limited knowledge about the frequency of PI is, at least in part, attributable to the lack of consistent way of reporting PI.
We have revised the abstract to say "Low levels of reported PPI may mask actual activity due to limited PPI reporting requirements." 11) First paragraph of the background section-the authors distinguish PI from lesser forms of involvement, including public 'engagement' in research. The authors should use a different word, given that patient and public 'engagement' is the term used to describe PI in the US.
Terminology for PPI and patient engagement varies by culture. We now more clearly describe our use of the terms. The reviewer suggests we use a different term for patient engagement but we feel that would add to the confusion as it is a widely used term in the UK. Instead we have acknowledged that terminology for PPI can be confusing and varies across cultures.
14) The term 'rate' in an epidemiologic context refers to the frequency of an event relative to time. For the measure in this paper, other terms like frequency, proportion or prevalence would be more appropriate.
We have revised this throughout the paper.
15) The information shared in this paper can serve as a baseline for funders, journals, academic institutions, and others interested in facilitating PI, against which future assessments can be compared.
No revision required.
16) Page 8-description of the REACT trial-more info is needed about how input was received from the public.
We have included all the information that was reported by the authors of the REEACT trial in the paper. This is another example of how examples of accurate reporting, agreement of common terms for PPI and good research practice might shape the future of PPI.
17) Page 8 -the last sentence "one study author named…."-this is a critical sentence explaining the impact of PI on that project. The paper would be strengthened if this sentence was written more clearly and in a more straightforward way.
We have revised the description of the PROSPER trial -see page 10. (2014) also includes guidance about reporting on patient engagement in research.
18) Concannon et al
We now mention Colcannon et al 2014 in the Discussion section.
19) The authors point to funding agencies requiring the 'declaration' of PI-would it be more accurate to say that increasingly funders are requiring PI?
Revised -see page 15 in Conclusions. "Funding organisations increasingly require researchers to involve patients and the public in their research,(48) but closer monitoring of how planned PPI documented in grant applications transfers into practice is needed."
20) The reference to support this point (#42) is not on the reference list This was a typo which we have now corrected.
VERSION 2 -REVIEW
REVIEWER
Lynne Gordon University of Hertfordshire UK REVIEW RETURNED 02-Feb-2018
GENERAL COMMENTS
Thank you to the authors for considering and incorporating the reviewer comments. This has been carried out effectively and I think the paper is much improved as a result. I have only two minor comments as follows:
The objectives section of the abstract is now a little clumsy and lacks flow. It would be worth reviewing this. In the process section the third sentence should commence; "data were..." rather than "data was..." REVIEWER Laura P Forsythe PCORI REVIEW RETURNED 15-Feb-2018
The authors have done an excellent job responding to my comments and those of the other reviewers. The paper is stronger and clearer and will make a meaningful contribution in the literature. This article provides useful benchmarks for reporting on PPI against which future work can be compared to determine the extent to which the culture of research is changing towards being more patientcentered. I have only minor recommendations.
The conclusions in the abstract suggest poor quality of PPI; however, there is no mention of quality in the body of the paper. Based on the discussion section, it seems the authors may mean the quality of reporting of PPI was poor.
Line 39, page 15 (tracked version)-This first sentence seems relevant to UK authors and not all authors. (some funding bodies or review boards have required this but not all)
A previous reviewer suggested the information about funding source and country of the corresponding author should be removed. I found this additional context to be helpful in interpretation of the findings. Given the cultural variation in implementation of PPI internationally, it was helpful to understand whether the PPI that is being reported is originating in countries/by funders where requirements for PPI are more long-standing and clearer vs. a variety of places. The Editor may wish to provide additional guidance on the relevance of this information to the paper.
VERSION 2 -AUTHOR RESPONSE
Dear BMJ Open Editorial Team,
